Skip to main content
Premium Trial:

Request an Annual Quote

New Kid on the Block

Yesterday, the Coriell Personalized Medicine Collaborative website went live. Unlike its personal genomics competitors, Coriell is offering a full genome scan plus a genetic health report and genetic counseling all for free. Genetic Future's Daniel MacArthur sees some catches, the biggest being that you actually have to go to their site in New Jersey to be tested and that they offer you limited access to your genetic markers. As for its threat to the top three, 23andMe and DecodeMe are safe, since they "both offer a wider range of applications than disease risk analysis (such as genetic ancestry and family member comparisons), and at least in 23andMe's case have a vastly superior PR engine,” he says.

Navigenics might have a harder time, since it plays in the same space of "sombre, medically-focused" gene scans. "Navigenics' product, which focuses only on these diseases, offers a negligible advantage over the Coriell scan in terms of clinical utility but costs $500 more. From most places in the US, it would be cheaper to travel to New Jersey and get Coriell's test than to fork out for Navigenics' product," he adds.

Filed under

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.